Prokidney (PROK) Cash from Financing Activities (2021 - 2026)
Prokidney's (PROK) quarterly Cash from Financing Activities came in at $215000.0 in Q1 2026, up 1891.67% year-on-year from $10795.0 in Q1 2025, and down 98.78% on a QoQ basis from $17.6 million in Q4 2025.
Prokidney (PROK) Cash from Financing Activities (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Cash from Financing Activities data on file, last reported at $215000.0 in Q1 2026.
- On a quarterly basis, Cash from Financing Activities rose 1891.67% year-over-year to $215000.0 in Q1 2026; TTM through Mar 2026 was $25.8 million, a 82.14% decrease from a year earlier, with the FY2025 full-year figure at $25.6 million, down 82.29% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $215000.0, down from $17.6 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for PROK reached as high as $507.5 million in Q3 2022 and fell as low as -$9.5 million in Q4 2023.
- Historically, Cash from Financing Activities has averaged $41.7 million across 5 years, with a median of $123000.0 in 2024.
- Across the five-year window, Cash from Financing Activities slumped 118800.0% in 2023 and jumped 1075807.69% in 2024, its largest moves.
- Year by year, Cash from Financing Activities stood at -$8000.0 in 2022, then slumped by 118800.0% to -$9.5 million in 2023, then surged by 101.29% to $123000.0 in 2024, then jumped by 14236.59% to $17.6 million in 2025, then sank by 98.78% to $215000.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $215000.0 in Q1 2026, $17.6 million in Q4 2025, and $8.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 30.14 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 53,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 68.63 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -538.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -802.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 238.74 Mn |
| 10 | Prokidney | 96.00 Mn | 96.00 Mn | - | 215,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215,000.00 |
| Mar 31, 2026 | 215,000.00 |
| Dec 31, 2025 | 17.63 Mn |
| Dec 31, 2025 | 17.63 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Sep 30, 2025 | 7.96 Mn |
| Jun 30, 2025 | -14,000.00 |
| Jun 30, 2025 | -14,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Mar 31, 2025 | -12,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Dec 31, 2024 | 123,000.00 |
| Sep 30, 2024 | 4.46 Mn |
| Sep 30, 2024 | 4.46 Mn |
| Jun 30, 2024 | 139.84 Mn |
| Jun 30, 2024 | 139.84 Mn |
| Mar 31, 2024 | -13,000.00 |
| Mar 31, 2024 | -13,000.00 |
| Dec 31, 2023 | -9.51 Mn |
| Dec 31, 2023 | -9.51 Mn |